Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Lyomark Pharma GmbH become majority shareholder of Lyocontract GmbH

Lyomark Pharma GmbH
Posted on: 03 Aug 17
Lyomark Pharma GmbH become majority shareholder of Lyocontract GmbH

We are pleased to announce that effective August 1st 2017 Lyomark Pharma GmbH shall become majority shareholder of Lyocontract GmbH. This will expand our combined capabilities and strengthen our overall position in the pharmaceutical industry.

Lyocontract is a state-of-the-art pharmaceutical manufacturing site with the capabilities of producing liquid and freeze-dried parenteral drugs in vials. The site received its manufacturing license in 2012 and has ever since earned the trust of numerous clients in Germany and abroad.

Both companies are privately held and will continue to be managed independently. The transaction will not affect ongoing activities at any of the Lyomark or Lyocontract facilities. Lyomark will continue to provide the current portfolio of products and registrations under Lyomark’s name to its customers. In case of any further questions do not hesitate to contact us.

Editor's Details

Monika Schweyer
Lyomark Pharma GmbH
www.lyomark.com
+49 89 45080878-0
info@lyomark.com

Last updated on: 03/08/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.